Format
Items per page
Sort by

Send to:

Choose Destination

Links from GEO DataSets

Items: 12

1.

Baseline serum anti-glycan antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Training IgG 1:50]

(Submitter supplied) Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. This study uses a high-throughput glycan microarray to assess correlations between a subject's overall survival after receiving PROSTVAC-VF and his baseline serum anti-glycan antibody levels. more...
Organism:
Quercus alba; Bothrops moojeni; Pachymenia carnosa; Medicago sativa; Pandalus borealis; Homo sapiens; Gossypium hirsutum; Rhodotorula; Gallus gallus; Mus musculus; Megathura crenulata; Bos taurus; Ovis aries; Frangula alnus; Senegalia senegal; Dermestes lardarius
Type:
Protein profiling by protein array
Platform:
GPL16242
28 Samples
Download data
Series
Accession:
GSE42019
ID:
200042019
2.

Baseline serum anti-glycan antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.
Organism:
Quercus alba; Pandalus borealis; Bothrops moojeni; Senegalia senegal; Dermestes lardarius; Ovis aries; Megathura crenulata; Frangula alnus; Gossypium hirsutum; Rhodotorula; Homo sapiens; Bos taurus; Mus musculus; Medicago sativa; Gallus gallus; Pachymenia carnosa
Type:
Protein profiling by protein array
Platforms:
GPL16242 GPL16262
564 Samples
Download data: TXT
Series
Accession:
GSE42184
ID:
200042184
3.

Baseline serum anti-glycan antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Validation Total Ig 1:200]

(Submitter supplied) Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. This study uses a high-throughput glycan microarray to assess correlations between a subject's overall survival after receiving PROSTVAC-VF and his baseline serum anti-glycan antibody levels. more...
Organism:
Medicago sativa; Gallus gallus; Megathura crenulata; Rhodotorula; Bos taurus; Ovis aries; Mus musculus; Frangula alnus; Senegalia senegal; Dermestes lardarius; Quercus alba; Bothrops moojeni; Pachymenia carnosa; Gossypium hirsutum; Pandalus borealis; Homo sapiens
Type:
Protein profiling by protein array
Platform:
GPL16242
113 Samples
Download data
Series
Accession:
GSE42179
ID:
200042179
4.

Baseline serum anti-glycan antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Validation Total Ig 1:50]

(Submitter supplied) Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. This study uses a high-throughput glycan microarray to assess correlations between a subject's overall survival after receiving PROSTVAC-VF and his baseline serum anti-glycan antibody levels. more...
Organism:
Gossypium hirsutum; Rhodotorula; Homo sapiens; Bos taurus; Mus musculus; Medicago sativa; Gallus gallus; Quercus alba; Pandalus borealis; Bothrops moojeni; Senegalia senegal; Pachymenia carnosa; Dermestes lardarius; Ovis aries; Megathura crenulata; Frangula alnus
Type:
Protein profiling by protein array
Platform:
GPL16242
113 Samples
Download data
Series
Accession:
GSE42176
ID:
200042176
5.

Baseline serum anti-glycan antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Validation IgM 1:50]

(Submitter supplied) Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. This study uses a high-throughput glycan microarray to assess correlations between a subject's overall survival after receiving PROSTVAC-VF and his baseline serum anti-glycan antibody levels. more...
Organism:
Gossypium hirsutum; Rhodotorula; Homo sapiens; Bos taurus; Mus musculus; Quercus alba; Megathura crenulata; Pandalus borealis; Ovis aries; Frangula alnus; Senegalia senegal; Dermestes lardarius; Medicago sativa; Gallus gallus; Bothrops moojeni; Pachymenia carnosa
Type:
Protein profiling by protein array
Platform:
GPL16242
113 Samples
Download data
Series
Accession:
GSE42175
ID:
200042175
6.

Baseline serum anti-glycan antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Validation IgG 1:50]

(Submitter supplied) Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. This study uses a high-throughput glycan microarray to assess correlations between a subject's overall survival after receiving PROSTVAC-VF and his baseline serum anti-glycan antibody levels. more...
Organism:
Medicago sativa; Gallus gallus; Ovis aries; Megathura crenulata; Frangula alnus; Rhodotorula; Bos taurus; Mus musculus; Senegalia senegal; Dermestes lardarius; Bothrops moojeni; Pachymenia carnosa; Quercus alba; Gossypium hirsutum; Pandalus borealis; Homo sapiens
Type:
Protein profiling by protein array
Platform:
GPL16242
113 Samples
Download data
Series
Accession:
GSE42163
ID:
200042163
7.

Baseline serum anti-glycan antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Training Total Ig 1:200]

(Submitter supplied) Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. This study uses a high-throughput glycan microarray to assess correlations between a subject's overall survival after receiving PROSTVAC-VF and his baseline serum anti-glycan antibody levels. more...
Organism:
Pandalus borealis; Frangula alnus; Senegalia senegal; Dermestes lardarius; Quercus alba; Ovis aries; Megathura crenulata; Gossypium hirsutum; Rhodotorula; Homo sapiens; Bos taurus; Mus musculus; Gallus gallus; Bothrops moojeni; Pachymenia carnosa
Type:
Protein profiling by protein array
Platform:
GPL16262
28 Samples
Download data
Series
Accession:
GSE42150
ID:
200042150
8.

Baseline serum anti-glycan antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Training Total Ig 1:50]

(Submitter supplied) Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. This study uses a high-throughput glycan microarray to assess correlations between a subject's overall survival after receiving PROSTVAC-VF and his baseline serum anti-glycan antibody levels. more...
Organism:
Gallus gallus; Mus musculus; Megathura crenulata; Rhodotorula; Bos taurus; Ovis aries; Frangula alnus; Senegalia senegal; Dermestes lardarius; Quercus alba; Bothrops moojeni; Pachymenia carnosa; Gossypium hirsutum; Pandalus borealis; Homo sapiens
Type:
Protein profiling by protein array
Platform:
GPL16262
28 Samples
Download data
Series
Accession:
GSE42145
ID:
200042145
9.

Baseline serum anti-glycan antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Training IgM 1:50]

(Submitter supplied) Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. This study uses a high-throughput glycan microarray to assess correlations between a subject's overall survival after receiving PROSTVAC-VF and his baseline serum anti-glycan antibody levels. more...
Organism:
Quercus alba; Bothrops moojeni; Pachymenia carnosa; Rhodotorula; Bos taurus; Ovis aries; Mus musculus; Frangula alnus; Senegalia senegal; Dermestes lardarius; Medicago sativa; Gallus gallus; Megathura crenulata; Gossypium hirsutum; Pandalus borealis; Homo sapiens
Type:
Protein profiling by protein array
Platform:
GPL16242
28 Samples
Download data
Series
Accession:
GSE42020
ID:
200042020
10.

A Simple, Inexpensive Strategy for Predicting Potential Beneficial Clinical Responses on Prostate Cancer Vaccine Therapy

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.
Organism:
Pandalus borealis; Oncorhynchus nerka; Ovis aries; Ceratonia siliqua; Frangula alnus; Senegalia senegal; Dermestes lardarius; Trypanosoma cruzi; Gallus gallus; Bothrops moojeni; Pachymenia carnosa; Quercus alba; Megathura crenulata; Gossypium hirsutum; Rhodotorula; Homo sapiens; Bos taurus; Mus musculus
Type:
Other
Platforms:
GPL20117 GPL20116
331 Samples
Download data
Series
Accession:
GSE68405
ID:
200068405
11.

Determination of ABO blood type for prostate cancer patients

(Submitter supplied) Purpose: This study uses a high-throughput glycan microarray to assign ABO blood type to patients from a clinical trial on PROSTVAC. The goal is to determine if blood type correlates with survival for patients treated with PROSTVAC Results: Blood types were assigned and type B and O patients were found to have longer survival than type A and AB patients Conclusion: Blood type may serve as a convenient method to identify patients likely to respond favorably to PROSTVAC therapy
Organism:
Frangula alnus; Gallus gallus; Homo sapiens
Type:
Other
Platform:
GPL20117
111 Samples
Download data: TXT
Series
Accession:
GSE68404
ID:
200068404
12.

Development of a glycan microarray based method for ABO blood typing

(Submitter supplied) Purpose: This study uses a high-throughput glycan microarray to develop a novel method to assign ABO blood type. The method will then be applied to samples from patients treated with PROSTVAC to determine if blood type correlates with survival Results: Many blood group A and B antigens correlate with blood type. Blood typing is best achieved using a combination of 10 signals Conclusion: ABO blood type can be determined with greater than 97% accuracy using only 4 microliters of serum.
Organism:
Gallus gallus; Ovis aries; Ceratonia siliqua; Megathura crenulata; Frangula alnus; Rhodotorula; Mus musculus; Bothrops moojeni; Senegalia senegal; Pachymenia carnosa; Dermestes lardarius; Quercus alba; Gossypium hirsutum; Pandalus borealis; Oncorhynchus nerka; Homo sapiens; Trypanosoma cruzi; Bos taurus
Type:
Other
Platform:
GPL20116
220 Samples
Download data: TXT
Series
Accession:
GSE68403
ID:
200068403
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

db=gds|term=|query=1|qty=20|blobid=NCID_1_22765114_130.14.22.215_9001_1503115295_1499823487_0MetA0_S_MegaStore_F_1|ismultiple=true|min_list=5|max_list=20|def_tree=20|def_list=|def_view=|url=/Taxonomy/backend/subset.cgi?|trace_url=/stat?
   Taxonomic Groups  [List]
Tree placeholder
    Top Organisms  [Tree]

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center